Pharmacogenomic Contributions to Trihexyphenidyl Biotransformation and Response in Children With Dystonic Cerebral Palsy

Recruiting now · Phase 1

Conditions studied: Pediatric Disorder, Genetic Predisposition, Dystonia, Secondary, Dystonia, Cerebral Palsy, Dystonic-Rigid, Cerebral Palsy, Dyskinetic, Trihexyphenidyl Adverse Reaction, Pharmacogenomic Drug Interaction

In brief

This study looks at how a medicine called trihexyphenidyl works in children with dystonic cerebral palsy. The study aims to understand how trihexyphenidyl is broken down and used in the body of pediatric patients and whether this is impacted by a person's genetics. Information from this study will also be used to design future clinical trials.

Key facts

Study ID

NCT06554288

Run by

Children's Mercy Hospital Kansas City

People needed

40

Starts

2024-10-15

Expected to finish

2029-12-31

Last updated by the study team

2026-06-24

Who can join

Age: 5 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Ages 5-17 years of age
• Diagnosis of cerebral palsy and dystonia causing interference
• Parent/legal guardian of a child with a diagnosis of cerebral palsy and dystonia
• Parent/legal guardian is willing and able to provide informed permission/assent for the study

You may not qualify if…

• Previously or currently taking trihexyphenidyl
• Patients turning 18 years of age within the study period (16 weeks from Study Day 1)
• A language barrier for the patient that precludes communication and/or the ability to complete study-related requirements

Where it is running

• Children's Mercy Hospital Kansas City — Kansas City, Missouri, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.